Inclusion Criteria:

- Written informed consent

- Patients with confirmed advanced solid tumors.

- No prior chemotherapy within 5 years of the diagnosis of SCLC (small cell lung
cancer).

- At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery.

- Laboratory criteria: Patients must have adequate bone marrow reserve and adequate
kidney and liver function.

Exclusion criteria:

- Women who are pregnant or lactating.

- Patients of child bearing potential refusing to practice adequate contraception.

- Patients with uncontrolled vomiting.

- Active infection.

- Patients with clinical evidence of any gastrointestinal (GI) conditions which would
alter GI absorption or GI motility.

- Patients requiring treatment with cyclosporin A.

- Severe medical problems other than the cancer, that would limit the ability of the
patient to follow study guidelines or expose the patient to extreme risk.

- Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational
therapy for cancer treatment.

- Use of investigational drug within 30 days prior to the first dose of study
medication.